

Title (en)

USE OF NMN TO REDUCE IMMUNODEPRESSION AND IMMUNOSENESCENCE

Title (de)

VERWENDUNG VON NMN ZUR VERRINGERUNG VON IMMUNODEPRESSION UND IMMUNSENESZENZ

Title (fr)

UTILISATION DE NMN POUR REDUIRE L'IMMUNODEPRESSION ET L'IMMUNOSENESCENCE

Publication

**EP 4157284 A1 20230405 (FR)**

Application

**EP 21728902 A 20210526**

Priority

- FR 2005739 A 20200529
- EP 2021064121 W 20210526

Abstract (en)

[origin: WO2021239850A1] The invention relates to nicotinamide mononucleotide, one of the pharmaceutically acceptable derivatives thereof, one of the pharmaceutically acceptable precursors thereof or one of the pharmaceutically acceptable salts thereof, for use in reducing immunosenescence and/or enhancing immune response to vaccination, and further relates to compositions containing same.

IPC 8 full level

**A61K 31/6615** (2006.01); **A61K 9/00** (2006.01); **A61K 31/706** (2006.01); **A61K 39/00** (2006.01); **A61P 37/02** (2006.01); **A61P 37/04** (2006.01)

CPC (source: EP US)

**A61K 31/6615** (2013.01 - EP US); **A61K 31/706** (2013.01 - EP US); **A61K 39/39** (2013.01 - EP); **A61P 37/02** (2018.01 - EP); **A61P 37/04** (2018.01 - EP); **A61K 2039/55561** (2013.01 - EP)

C-Set (source: EP)

1. **A61K 31/706 + A61K 2300/00**
2. **A61K 31/6615 + A61K 2300/00**

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

**FR 3110836 A1 20211203**; **FR 3110836 B1 20230616**; CN 115968294 A 20230414; EP 4157284 A1 20230405; US 2023136569 A1 20230504; WO 2021239850 A1 20211202

DOCDB simple family (application)

**FR 2005739 A 20200529**; CN 202180041663 A 20210526; EP 2021064121 W 20210526; EP 21728902 A 20210526; US 202117927478 A 20210526